Gapping down
Other news:
- LOGC -17.7% (to voluntarily delist from The Nasdaq Global Market at the close on June 2 and to begin trading on the OTCQB Venture Market)
- ARVN -6.9% (Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer)
- LIF -3.9% (Proposes offering of $250 mln of convertible senior notes due 2030)
- REPL -2.4% (Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting)
- LI -1.3% (May deliveries)
- AZN -1.1% (ASCO presentations)
- ACTU -1.1% (Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer)
- CP -1% (receives arbitration decision establishing new TCRC collective agreements)